Danish National Genome Center selects QIAGEN for variant interpretation in oncology genome sequencing
13 Junho 2023 - 5:05PM
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced
that its variant interpretation and reporting software, QIAGEN
Clinical Insight (QCI) Interpret, is being deployed as a part of a
national initiative in Denmark to offer sequencing-based solutions
for cancer patients.
The QCI Interpret solution was chosen by the
Danish National Genome Center to provide interpretation of oncology
results generated from whole-genome sequencing (WGS) data. The
initiative is part of a larger personalized medicine strategy that
aims to provide WGS as the standard-of-care for relevant patient
groups throughout Denmark.
Denmark is one of the first countries in the
world to implement WGS as standard-of-care for oncology at this
scale, and to adopt QCI Interpret to support the national
initiative. The country aims to gain sufficient genetic data to
truly utilize the power of genomics in personalized medicine to
improve outcomes for patients through better cancer diagnosis and
treatment decisions.
“We are pleased to partner with the Danish
National Genome Center in this landmark program to provide
nationwide access to the power of sequencing for cancer patients in
Denmark,” said Jonathan Sheldon, Executive Vice President and Head
of QIAGEN Digital Insights. “Denmark is taking a visionary approach
to aggregating genomic data and combining it with clinical
information on cancer patients to develop enhanced
population-specific knowledge and reference sets for the country’s
residents. This will serve as a foundation for effective precision
medicine capabilities for years to come. This partnership also
demonstrates QIAGEN’s ability to support national precision
medicine programs in terms of infrastructure and technology
support. Together we are determined to advance the power of
molecular insights from bench to bedside.”
Denmark has strict requirements for data privacy
and security, requiring all data to be processed and stored within
the country and only accessed from within the National Genome
Center infrastructure. QCI Interpret, allows authorized staff from
labs across the country to interpret whole genome sequencing data
consistently and efficiently while meeting data privacy and
security requirements.
“QCI Interpret delivers evidence-based variant
interpretation and reporting, adheres to the highest level of data
security and privacy, and allows for flexibility at distributed
testing sites throughout the country that use different
next-generation sequencing instruments. The platform is an agnostic
solution that can be easily integrated with any pipeline to enable
users to go from variant calls to final report within minutes,”
said Dan Richards, Vice President of Clinical Product Management at
QIAGEN Digital Insights.
Test analysis and interpretation are key
barriers to implementing WGS at-scale. The Danish National Genome
Center selected QCI Interpret to streamline and accelerate the
interpretation, and reporting process. Connected to the QIAGEN
Knowledge Base, a comprehensive, manually curated resource that is
updated weekly, QCI Interpret dynamically computes pathogenicity
and actionability based on professional guidelines for every
variant in over 31,000 cancer types. In addition, users have access
to over 460,000 preformulated, oncologist-reviewed variant impact
summaries to build custom, patient-specific reports with the latest
evidence and prognostic information, as well as biomarker-directed
therapies and clinical trials.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare), Applied Testing (primarily
forensics), Pharma (pharma and biotech companies) and Academia
(life sciences research). As of March 31, 2023, QIAGEN
employed more than 6,200 people in over 35 locations worldwide.
Further information can be found at http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, including those
products used in the response to the COVID-19 pandemic, timing for
launch and development, marketing and/or regulatory approvals,
financial and operational outlook, growth and expansion,
collaborations, markets, strategy or operating results, including
without limitation its expected adjusted net sales and adjusted
diluted earnings results, are forward-looking, such statements are
based on current expectations and assumptions that involve a number
of uncertainties and risks. Such uncertainties and risks include,
but are not limited to, risks associated with management of growth
and international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, including the
breadth and duration of the COVID-19 pandemic and its impact on the
demand for our products and other aspects of our business, or other
force majeure events; as well as the possibility that expected
benefits related to recent or pending acquisitions may not
materialize as expected; and the other factors discussed under the
heading “Risk Factors” contained in Item 3 of our most recent
Annual Report on Form 20-F. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.
Category: Corporate
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Daniela Eltrop
QIAGEN N.V.
+49 2103 29 11676
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024